Lighter chemo, same punch? new combo aims to spare older lung cancer patients harsh side effects

NCT ID NCT06731413

Recruiting now Disease control Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a lower dose of chemotherapy combined with an immunotherapy drug can be a safer and still effective first treatment for older adults (70+) or those who are frail with advanced non-small cell lung cancer. The main goal is to see if fewer people have to stop chemo due to side effects. About 40 participants will receive this reduced-dose combination, and doctors will track how well the cancer responds.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL LUNG CANCER METASTATIC NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER NSCLC

Contacts and locations

Locations

VCU Health Tappahannock Hospital
RECRUITING

Tappahannock, Virginia, 22560, United States
Virginia Commonwealth University
RECRUITING

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.